You are viewing: UK Biobanking Market analysis
Part of: Biobanking Market (Global)

The UK Biobanking Market was valued at $396.9 Million in 2025 and projected to reach to $617.2 Million by 2030, representing a compound annual growth rate of 9.2%. The UK biobanking market is poised for sustained expansion, growing at a CAGR of 9.2% from 2025 to 2030, reaching £617.2 million by forecast end.

UK Biobanking Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Biobanking Market Trends and Insights

  • The UK's advanced healthcare infrastructure, strong regulatory framework, and significant investment in precision medicine are driving adoption of biobanking solutions across research institutions, hospitals, and pharmaceutical companies.
  • The UK's position as a global leader in genomic research and personalized medicine initiatives continues to accelerate demand for sophisticated sample storage and management systems. Key drivers of growth in the UK biobanking market include increasing prevalence of chronic diseases, rising government funding for biomedical research, and growing collaboration between UK academic institutions and industry partners.
  • The UK's National Health Service (NHS) and numerous biobanks are investing heavily in digital infrastructure and automation technologies to enhance sample quality and accessibility.
  • Between 2025 and 2030, the UK market will benefit from regulatory harmonization with international standards and expanding applications in regenerative medicine and cell therapy development..

Key Market Statistics

  • CAGR (2025-2030) 9.2% CAGR
  • Market Size, 2025 ~USD 396.9 Million
  • Forecast, 2030 ~USD 617.2 Million
  • Country UK

UK Biobanking Market Overview

Market Valuation :

The UK biobanking market is valued at £396.9 million in 2025, with strong growth trajectory positioning it as a key European hub for biobanking infrastructure and services.

Regulatory Excellence :

The UK's stringent regulatory framework and compliance standards, including MHRA oversight and GDPR requirements, create a trusted environment for biobank operations and international partnerships.

Precision Medicine Investment :

Significant government and private sector investment in precision medicine initiatives, including the NHS Genomic Medicine Service, is driving demand for advanced biobanking solutions across the UK.

Healthcare Infrastructure :

The UK's advanced healthcare system, with established NHS networks and leading research institutions, provides a robust foundation for biobanking adoption and clinical integration.

UK Biobanking Market Dynamics

  • This growth is underpinned by increasing adoption of biobanking technologies across NHS trusts, academic medical centers, and pharmaceutical research organizations seeking to leverage biological samples for precision medicine and drug development.
  • The UK's commitment to genomic research and personalized healthcare initiatives continues to create favorable conditions for market expansion. Key drivers include rising demand for biospecimen management solutions, growing collaborations between UK research institutions and global pharmaceutical companies, and enhanced funding for biomedical research.
  • The integration of biobanking with digital health platforms and artificial intelligence applications presents additional growth opportunities.
  • UK biobanks are increasingly positioning themselves as critical infrastructure for translational research, supporting the nation's ambitions in precision medicine and life sciences innovation..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • The UK biobanking market will grow from £396.9M (2025) to £617.2M (2030), representing a 9.2% CAGR.
    • The UK's advanced healthcare system and NHS infrastructure provide a strong foundation for biobanking expansion and digital integration.
    • UK investment in genomic research and precision medicine initiatives is driving increased demand for biobanking infrastructure and services.
    • Regulatory alignment and automation technologies will enhance sample management efficiency across UK biobanks through 2030.

    Biobanking Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment SOFTWARE (Offering)
    Forecast Period 2025–2030
    Growth Rate CAGR of 9.1% from 2025 to 2030
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 7.65 (2025)
    Revenue Forecast (Billions) ~USD 11.82 (2030)
    Segments Covered Offering, Type, Operation Type, Workflow, Sample Type, Ownership, Application, End User

    UK Biobanking Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services
    • Software

    By Type

    • Alarm & Monitoring Systems
    • Clinical Research
    • Consumables
    • Cryogenic Storage Systems
    • Equipment
    • Freezers & Refrigerators
    • Life Science Research
    • Life Sciences Research
    • Other Equipment & Accessories
    • Other Services
    • Physical Biobanking Services
    • Temperature & Humidity Control Systems
    • Thawing Equipment
    • Virtual Biobanking Services

    By Operation Type

    • Automated Equipment
    • Automated Operations
    • Manual Equipment
    • Manual Operations

    By Workflow

    • Sample Analysis
    • Sample Collection & Storage
    • Sample Processing
    • Transport & Logistics

    By Sample Type

    • Biological Fluids
    • Blood Products
    • Human Waste Products
    • Nucleic Acids
    • Solid Tissues & Organs
    • Stem Cells & Cell Lines

    By Ownership

    • Academic & Research Institution Biobanks
    • Hybrid/Ppp Model
    • National/Regional Agencies
    • Other Ownership Models
    • Private/ Commercial Biobanks

    By Application

    • Diagnostic Applications
    • Other Applications
    • Research Applications
    • Therapeutic Applications

    By End User

    • Academic & Research Institutes
    • Biobanks
    • Cros
    • Hospitals & Diagnostic Laboratories
    • Pharma-Biotech Companies & Cros

    UK: BIOBANKING SERVICES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES25.125.928.130.833.937.441.445.810.3
    HOSPITALS & DIAGNOSTIC LABORATORIES15.515.917.218.820.622.624.927.59.8
    PHARMA-BIOTECH COMPANIES & CROS60.362.467.974.682.391100.911210.5
    TOTAL100.8104.2113.3124.3136.9151.1167.2185.310.3

    UK: BIOBANKING PRODUCTS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    BIOBANKS185.2190.1202.1217.2234.9255.2278.3304.78.6
    CROS53.854.95861.966.571.877.884.67.9
    TOTAL239244.9260279.1301.5327356.1389.38.4

    Target Audience

    • UK Pharmaceutical Companies : Need detailed market intelligence on biobanking adoption rates and biospecimen availability across UK research institutions to optimize clinical trial recruitment and drug development timelines.
    • NHS Trusts & Hospital Networks : Require market data on biobanking best practices, technology solutions, and implementation costs to enhance clinical research capabilities and support precision medicine initiatives across their networks.
    • Academic Research Institutions : Seek comprehensive market analysis to benchmark their biobanking operations, identify funding opportunities, and understand competitive positioning within the UK research ecosystem.
    • Biotech & Life Sciences Investors : Need UK-specific market forecasts and growth projections to evaluate investment opportunities in biobanking infrastructure, digital solutions, and precision medicine platforms targeting the British market.
    • Healthcare Technology Vendors : Require detailed market segmentation and customer insights specific to UK biobanks to develop targeted product strategies, identify key accounts, and plan market expansion initiatives.

    Key Companies in the UK Biobanking Market

    CompanyHQOwnershipStrongest segments
    MAXCYTE, INCUnited StatesPublic CompanyExPERT ATx and STx instruments,ExPERT GTx and VLx instruments,Disposable processing assemblies (PAs),
    HDFC BANKIndiaPublic CompanyRetail Banking (deposits, consumer and home loans, cards),Wholesale Banking (corporate, SME, supply chain, trade),Treasury and Markets (money market, derivatives, investments),
    STANDARD CHARTEREDUnited KingdomPrivate CompanyFinancial Markets (FX, rates, commodities, credit),Transaction Banking (trade, cash, liquidity, custody),Corporate & Structured Finance,
    YES BANKIndiaPublic CompanyRetail banking (deposits, cards, consumer loans),Corporate and wholesale banking,MSME and business banking,
    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITEDIndiaPublic CompanyVehicle Finance (CV, PV, 2W/3W, tractors, construction equipment),Loan Against Property (LAP) and SME Secured Loans,Home Loans and Home Extensions,
    AXIS MUTUAL FUNDIndiaPrivate CompanyActively managed equity funds,Hybrid and asset allocation funds,Debt and money market funds,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    PHC HOLDINGS CORPORATIONJapanPublic CompanyDiabetes Management,Diagnostic and Life Sciences,Healthcare Solutions (EMR, billing, pharmacy, wellness),
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
    AVANTOR, INC.United StatesPublic CompanyMaterials and consumables,Equipment and instrumentation,Services and specialty procurements,
    CRYOPORTUnited StatesPublic CompanyLife Sciences Services (logistics, biostorage, bioservices, consulting),Life Sciences Products (cryogenic freezers, dewars, accessories),IoT and digital monitoring solutions,
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    LABCORPUnited StatesPublic CompanyRoutine and chronic-disease diagnostics (chemistry, hematology, A1C, thyroid, PSA, urinalysis),Specialty and esoteric testing (gene-based, oncology, cardiovascular, endocrinology, infectious disease),Biopharma Laboratory Services and clinical trial support,
    EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics,
    HAIER BIOMEDICALChinaPublic CompanyULT freezers and low-temperature storage,Pharmacy and vaccine refrigerators/freezers, cold rooms,Blood bank and transfusion chain equipment,
    HAMILTON COMPANYUnited StatesPublic Investment FirmFund-of-funds (primary and secondary),Direct credit,Direct and co-investments / buyouts,

    MAXCYTE, INC

    MAXCYTE, INC is a public company based in the United States that was founded in 1998 and currently employs 91 people.

    HDFC BANK

    HDFC BANK is a public company based in India that was founded in 1994 and currently employs 212,958 people.

    STANDARD CHARTERED

    STANDARD CHARTERED is a private company based in the United Kingdom that was founded in 1853 and currently employs 66,524 people.

    YES BANK

    YES BANK is a public company based in India that was founded in 2003 and currently employs 29,577 people.

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED is a public company based in India that was founded in 1978 and currently employs 51,320 people.

    AXIS MUTUAL FUND

    AXIS MUTUAL FUND is a private company based in India that was founded in 2009.

    THERMO FISHER SCIENTIFIC INC.

    THERMO FISHER SCIENTIFIC INC. is a public company based in the United States that was founded in 1956 and currently employs 125,000 people.

    PHC HOLDINGS CORPORATION

    PHC HOLDINGS CORPORATION is a public company based in Japan that was founded in 1948 and currently employs 8,647 people.

    QIAGEN

    QIAGEN is a public company based in the Netherlands that was founded in 1984 and currently employs 5,500 people.

    MERCK KGAA

    MERCK KGAA is a public company based in Germany that was founded in 1668 and currently employs 59,077 people.

    AVANTOR, INC.

    AVANTOR, INC. is a public company based in the United States that was founded in 1904 and currently employs 13,500 people.

    CRYOPORT

    CRYOPORT is a public company based in the United States that was founded in 1999 and currently employs 688 people.

    AGILENT TECHNOLOGIES, INC.

    AGILENT TECHNOLOGIES, INC. is a public company based in the United States that was founded in 1999 and currently employs 18,000 people.

    LABCORP

    LABCORP is a public company based in the United States that was founded in 1995 and currently employs 66,385 people.

    EUROFINS SCIENTIFIC

    EUROFINS SCIENTIFIC is a public company based in Luxembourg that was founded in 1987 and currently employs 65,694 people.

    HAIER BIOMEDICAL

    HAIER BIOMEDICAL is a public company based in China that was founded in 2005 and currently employs 2,945 people.

    HAMILTON COMPANY

    HAMILTON COMPANY is a public investment firm based in the United States that was founded in 1991 and currently employs 785 people.

    Reasons to Buy this Report

    • UK-Specific Market Sizing : Access precise valuation data for the UK biobanking market with detailed 2025-2030 forecasts, enabling accurate business planning and investment decisions tailored to the British market landscape.
    • Regulatory & Compliance Insights : Understand UK-specific regulatory requirements, MHRA standards, and GDPR compliance frameworks essential for operating biobanking services and establishing partnerships within the UK healthcare system.
    • NHS Integration Opportunities : Identify strategic opportunities for biobanking solution integration with NHS trusts and the NHS Genomic Medicine Service, including procurement pathways and partnership models specific to UK healthcare.
    • Competitive Landscape Analysis : Gain insights into UK-based biobanking providers, academic institutions, and pharmaceutical partnerships, enabling informed competitive positioning and market entry strategies for the British market.
    • Growth Driver Assessment : Evaluate UK-specific growth catalysts including precision medicine investments, genomic research funding, and life sciences sector expansion to prioritize market opportunities and resource allocation.

    Frequently asked questions

    What is the current size of the UK biobanking market?

    The UK biobanking market was valued at £396.9 million in 2025 and is projected to reach £617.2 million by 2030.

    What is the growth rate of the UK biobanking market?

    The UK biobanking market is expected to grow at a compound annual growth rate (CAGR) of 9.2% from 2025 to 2030.

    What factors are driving growth in the UK biobanking market?

    Key growth drivers include increased government funding for biomedical research, rising prevalence of chronic diseases, NHS digital infrastructure investments, and expanding precision medicine applications across the UK.

    Which sectors are the primary users of biobanking services in the UK?

    Primary users of UK biobanking services include pharmaceutical companies, academic research institutions, NHS hospitals, contract research organizations, and regenerative medicine developers.

    How is the UK biobanking market expected to evolve by 2030?

    By 2030, the UK biobanking market will see increased automation, enhanced digital infrastructure, regulatory harmonization with international standards, and expanded applications in cell therapy and personalized medicine.

    RESEARCH METHODOLOGY

    This study involved four major activities to estimate the current size of the biobanking market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. Secondary sources for this study included publications from government sources, such as the European, Middle Eastern & African Society for Biopreservation and Biobanking (ESBB), Biobanking and BioMolecular Resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), International Society for Biological and Environmental Repositories (ISBER), National Institutes of Health (NIH), and the US Food and Drug Administration (US FDA), as well as ScienceDirect and several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Biobanking market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:

    Biobanking Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the biobanking market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Biobanking Market : Top-Down and Bottom-Up Approach

    Biobanking Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.

    Market Definition

    Biobanking involves collecting, processing, storing, and managing biological samples—such as blood, tissues, stem cells, nucleic acids, and other human-derived materials—for research, diagnostic, and therapeutic applications. The market includes equipment, consumables, software, and services used by CROs, biobanks, pharmaceutical and biotechnology companies, and academic and research institutions. These entities manage diverse sample types, including blood products, human tissues, stem cells and cell lines, nucleic acids, biological fluids, and human waste products, using manual or automated systems depending on technological adoption. The market is also segmented by ownership models, including academic and research institutions, national and regional agencies, private organizations, and other entities.

    Key Stakeholders

    • Academic & Research Institutes
    • Biobanks
    • Contract Research Organizations (CROs)
    • Market Research and Consulting Firms
    • Pharmaceutical and Biotechnology Companies
    • Regulatory Agencies
    • Venture Capitalists
    • Forensics Labs
    • Government organizations
    • Private research firms
    • Hospitals and Diagnostic Laboratories

    Report Objectives

    • To define, describe, and forecast the biobanking market by offering, equipment-operation type, service-ownership, product-sample type, application, product-end user, service-end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biobanking market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market share and core competencies
    • To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:

    Geographical Analysis

    • Further breakdown of Rest of Europe biobanking market, by country
    • Further breakdown of Rest of Asia Pacific biobanking market, by country

    Comapany Information

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

     

    Get the Full Biobanking Market Report

    Full forecast, segment splits, and company analysis for all Biobanking Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status